Investigate the causality and genetic association between 1

migraine and Parkinson's disease 2

- 3
- 4 Ming-Gang Deng^{1,2,†}, Xiuxiu Zhou^{1,2,†}, Fang Liu³, Kai Wang⁴, Lingli Luo⁵, Min-Jie Zhang³, Qianqian Feng³,

5 Jiewei Liu^{1,2}

- 6
- 7 ¹ Department of Psychiatry, Wuhan Mental Health Center, Wuhan 430012, Hubei, China
- 8 ² Department of Psychiatry, Wuhan Hospital for Psychotherapy, Wuhan 430012, Hubei, China
- 9 ³ School of Public Health, Wuhan University, Wuhan 430071, Hubei, China
- ⁴ Department of Public Health, Wuhan Fourth Hospital, Wuhan 430033, Hubei, China 10
- 11 ⁵ Department of Pathophysiology, School of Basic Medicine and Tongji Medical College, Huazhong
- 12 University of Science and Technology, Wuhan, 430030, China
- 13
- 14 ⁺ These authors contributed equally to this work.
- 15

17

- *Correspondence to: Ming-Gang Deng (deng.minggang@outlook.com) 16
 - Jiewei Liu (liujiewei@hust.edu.cn)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18 Abstract

- 19 Background: The relationship between migraine and Parkinson's disease (PD) remains controversial. We 20 intend to investigate the causal and genetic association between migraine and PD. 21 Methods: Data related to migraine [any migraine (AM), migraine without aura (MO), and migraine with 22 aura (MA)] and PD were respectively obtained from the latest Genome-wide meta-analysis conducted by 23 the International Headache Genetics Consortium and the International Parkinson's Disease Genomics Consortium. Univariate Mendelian Randomization (UMR) and multivariate MR (MVMR) were conducted 24 25 to estimate their bidirectional causality, and global/local genetic correlation and tissue expression analyses 26 were utilized to assess their genetic associations. 27 **Results:** The UMR presented that AM (OR: 1.016, 95% CI: 0.908-1.135, *p* = 0.785), MO (OR: 0.944, 95% CI: 28 0.836-1.067, p = 0.358) and MA (OR: 1.006, 95% CI: 0.951, 1.064, p = 0.846) were unlikely to be associated 29 with PD risk. Similarly, the reverse UMR analyses demonstrated that PD was unrelated to the risks of 30 migraine and its subtypes. These null associations were supported by the MVMR when adjusted for 31 coronary heart disease and hypertension. The global genetic correlation analyses presented that AM (r_q = 32 -0.061, p = 0.127), MA ($r_{q} = -0.047$, p = 0.516), MO ($r_{q} = -0.063$, p = 0.492) were generally not related to 33 PD, and the local genetic correlation analyses shown they were also uncorrelated in any region. 34 Additionally, the tissue expression analyses found they had no shared tissues. 35 **Conclusion:** This study suggested no causality or association between migraine and PD from the genetic
- 36 perspective.

37 **Keywords:** Migraine; Parkinson's disease; Causality; Genetic association.

38 **1. Introduction**

Migraine is a highly prevalent brain disorder characterized by recurrent headache attacks, often accompanied by symptoms such as photophobia, phonophobia, nausea, and vomiting¹. According to whether the attack was preceded by an aura, migraine could be further classified into migraine without aura (MO) and migraine with aura (MA)¹. Recent studies have confirmed that migraine is bi-directionally related to the risk of multiple diseases including major depressive disorder², epilepsy³, coronary artery disease⁴, etc.

Parkinson's disease (PD) is a chronic progressive neurodegenerative movement disorder characterized by 45 a profound and selective loss of nigrostriatal dopaminergic neurons⁵. Considering the shared involvement 46 47 that has been reported among neurotransmitters, the brainstem, and hypothalamic regions in both migraine and PD, many epidemiology studies explored their relationship but have not obtained consent 48 vet. Some studies concluded that migraine was not related to the risk of PD⁶⁻⁸, nevertheless, recent studies 49 50 found people with migraine were more susceptible to suffering from PD^{9,10}. Meanwhile, Nunes et al. 51 demonstrated that PD patients had a lower lifetime prevalence of headache than controls¹¹, and a multi-52 center case-controlled study found the overall headache and migraine severity reduced after PD onset¹², 53 which together suggested a potential causal effect of PD on migraine. Therefore, the recent meta-analysis 54 stated that the exact causal relationship between migraine and PD was still ambiguous¹³.

55 Migraine and PD have both been reported to have substantial genetic backgrounds^{14,15}, and the recent 56 genome-wide association studies (GWASs) have identified plenty of genome-wide significant genetic 57 variations related to migraine^{16,17} and PD¹⁸, which provided an opportunity to investigate their relationship 58 from the genetic perspective. Mendelian Randomization (MR), which uses genetic variants associated with 59 specific exposures as the instrumental variables, could overcome the limitations of conventional 60 observational studies such as reverse causality and residual confusion¹⁹ to provide a more robust causal

estimate of exposures on outcomes because germline genetic variants are randomly inherited from parents to offspring²⁰. Therefore, we would like to utilize MR to examine the bidirectional causal relationship between migraine and PD based on the GWAS summary statistics. Genetic correlation and tissue enrichment analyses were also conducted to seek their genetic associations. We hypothesize that migraine and PD were not correlated from the genetic perspective based on current data.

66 2. Methods

67 2.1. Data sources

68 This study is designed to investigate the bidirectional causal relationship and the genetic association 69 between migraine and PD, an overview of this study design is presented in **Supplementary Fig. 1**. Genetic variants associated with any migraine (AM) were obtained from the latest Genome-wide meta-analysis by 70 71 Hautakangas et al¹⁶, which included a total of 102,084 cases and 771,257 controls from the International 72 Headache Genetics Consortium (IHGC)-2016¹⁷, 23andMe, UK Biobank, GeneRISK, and Nord-Trøndelag 73 Health Study. In this meta-analysis, migraine was defined as self-reported or based on the International 74 Classification of Headache Disorders second edition criteria. Due to the data release policy, we retrieved 75 the summary-level statistics with the samples from 23andMe being excluded, and this elimination resulted 76 in a subsample of 589,356 (48,975 cases and 540,381 controls).

Additionally, to evaluate the relationship between PD and migraine subtypes [migraine without aura (MO) and migraine with aura (MA)], genetic data were obtained from the IHGC-2016¹⁷. MO participants consisted of 8,348 cases and 139,622 controls from 11 studies from the Danish Headache Center, German migraine without aura, etc. MA samples composed of 6,332 cases and 144,883 controls from 12 studies including Danish Headache Center, Dutch Migraine with aura, Nord-Trøndelag Health Study, etc. Detailed information can be found in the original paper¹⁷.

PD associated genetic variants were obtained from the International Parkinson's Disease Genomics Consortium¹⁸, which included 37,688 cases, 18,618 UK Biobank proxy cases, and about 1.4 million controls from 17 cohorts. As GWAS results of several datasets (such as 23andMe) were not publicly available, genome-wide associations of 33,674 cases and 449,056 controls were used in this study.

87 **2.2.**

2. Mendelian Randomization

88 To ensure the causal estimates from the MR are valid, the genetic variants should satisfy three critical 89 assumptions: (1) the relevance assumption indicates the genetic variants are strongly associated with the 90 exposure, (2) the independence assumption implies genetic variants are not associated with any potential 91 confounder of the exposure-outcome association and (3) the exclusion restriction assumption refers that 92 variants do not affect outcome independently of exposure²¹. For the bidirectional MR causal estimates, 93 the analyses were performed in two directions with genetic variants with migraine (1) as exposure: to 94 evaluate whether individuals suffered from migraine were more likely to develop PD, and (2) as outcome: 95 to assess whether people with PD were less likely to report migraine.

96 The procedures of instrument selection in our study were in line with the aforementioned three critical assumptions. For the relevance assumption, SNPs were initially screened at genome-wide significance (P 97 98 < 5×10⁻⁸), and if no SNP were discovered, this threshold was loosened to $P < 1 \times 10^{-5}$ as previous studies 99 did^{2,22}. To avoid the bias triggered by weak instruments, the F statistic was calculated and SNPs with an F 100 statistic lower than 10 were considered as weak instruments and excluded^{23,24}. For the exclusion restriction 101 assumption, the retained SNPs were clumped for linkage disequilibrium (LD) with the European samples 102 from the 1000 Genomes Project²⁵ as the reference panel using the PLINK tool (version 1.9)²⁶. The clumping 103 R² cut-off was set as 0.001 within a window of 10 Mb. If an obvious LD effect was detected, only the SNP 104 with the lowest *p*-value would be kept. Additionally, the modified Cochran's Q test²⁷ was performed to 105 identify outlier pleiotropic SNPs as the Q statistic much larger than N_{SNP}-1 suggests violation of

106 independence or exclusion restriction assumption²⁸, and these outlier pleiotropic SNPs would be excluded. As for the independence assumption, we used the PhenoScanner V2 tool²⁹ to assess whether the selected 107 108 SNPs were related to the confounders or risk factors in the relationship between migraine and PD. If 109 obvious confounders were identified, they would be further adjusted in the multivariate MR (MVMR) 110 analyses, which is an extension of MR that can detect the causal effects of multiple risk factors jointly³⁰. 111 The inverse variance weighted (IVW) method was adopted as the primary method to infer the causal relationship between migraine and PD, which used a meta-analysis approach that combined the Wald 112 estimate for each SNP to obtain an overall estimate and was the most efficient method when average 113 114 pleiotropic effect did not exist. Additionally, three well-established and horizontal pleiotropy robust methods including MR-Egger, weighted median, and MR-PRESSO (Pleiotropy RESidual Sum and Outlier) 115 were supplemented to validate the IVW estimates. Sensitive analyses by the MR-Egger regression intercept 116 and leave-one-out analyses were respectively conducted to check whether directional horizontal 117 118 pleiotropy or a single SNP was driving the results of MR analyses.

119 The MR analyses were performed in R software (version 4.3.1) with *TwoSampleMR* (version 0.5.7),

120 *MendelianRandomization* (version 0.8.0), *MRPRESSO* (version 1.0), and *RadialMR* (version 1.1) packages.

121

2.3. Genetic association analyses

122 2.3.1. Global Genetic Correlation

The LD score regression³¹, which could evaluate the genetic heritability correlation cross traits based on GWAS summary statistics, was adopted to evaluate the genetic correlation (r_g) between migraines and PD, with European ancestry samples from the 1000 Genomes Project being the reference panel²⁵. This procedure was performed in R software (version 4.3.1) with the *ldscr* (version 0.1.0) package.

127 2.3.2. Local Genetic Correlation

To investigate whether migraine and PD were locally correlated at a defined genomic region, ρ -HESS (Heritability Estimation from Summary Statistics)^{32,33}, which was a software package for estimating and visualizing local SNP-heritability and genetic correlation from GWAS summary association data, was utilized. In this algorithm, the entire genome was partitioned into 1703 independent regions across all chromosomes (sex chromosomes excluded) based on the European population LD patterns. The local genetic correlation between migraine and PD was quantified in particular regions, and the Bonferroni corrected *P*-value of *P* < 0.05/1703 was set as the significance threshold.

135 2.3.3. Tissue expression analyses

To explore whether the GWAS data related to migraine and PD were enriched in some specific and same 136 137 tissues, we implemented the MAGMA (Multi-marker Analysis of GenoMic Annotation)³⁴ in FUMA³⁵ (https://fuma.ctglab.nl/) to perform the tissue expression analyses, which was based on the expression 138 data from 54 tissues of GTEx V8³⁶. The maximum p-value of lead SNPs was set as $P < 5 \times 10^{-8}$, and if no 139 SNP met this criterion, we loosened it to $P < 1 \times 10^{-5}$. The upstream and downstream windows size of genes 140 to assign SNPs were set to 35 and 10kb³⁷, respectively. The other parameters and settings were used 141 142 default. Bonferroni correction was applied and a *P*-value threshold of P < 0.05/54 was set to obtain significant findings. 143

- 144 **3. Results**
- 145 3.1. Mendelian Randomization
- 146 **3.1.1. Univariate Mendelian Randomization**

The selected instrumental variants based on prior criteria were presented in Supplementary Table 1-2.
The total proportion of variance explained by their corresponding data sets ranged from 3.986% to
21.772%.

150 The results of MR causal inference between migraine and PD are illustrated in **Table 1**. The IVW method 151 presented that genetically predicted liability to AM (OR: 1.016, 95% CI: 0.908-1.135, P = 0.785), MO (OR: 152 0.944, 95% CI: 0.836-1.067, P = 0.358) and MA (OR: 1.006, 95% CI: 0.951-1.064, P = 0.846) were unlikely to 153 be associated with PD risk. Regarding the reverse association, the IVW method also demonstrated that 154 PD was not related to the risk of AM (OR: 1.003, 95% CI: 0.975-1.032, P = 0.817), MO (OR: 0.956, 95% CI: 155 0.893-1.025, P = 0.207) and MA (OR: 1.032, 95% CI: 0.955-1.115, P = 0.430). These null associations were generally supported by the supplemented analyses by MR-Egger, weighted median, and MR-PRESSO 156 methods. The scatter plot of SNP effects on migraine versus PD, and PD versus migraine was presented in 157 158 Supplementary Fig. 2. Sensitive analyses by the MR-Egger regression intercept showed there was no directional horizontal pleiotropy affecting the overall causal estimates (Table 1) and leave-one-out 159 160 analyses implied the overall effect was not driven by a single SNP (Fig. 2).

161 3.1.2. Multivariate Mendelian Randomization

As shown in **Supplementary Table S1-S2**, genetic variants associated with migraine were meanwhile related to coronary heart disease and hypertension, which have been demonstrated as risk factors of PD^{38,39}, while no obvious confounding phenotypes were identified in genetic variants related to PD. Therefore, we performed MVMR analyses to control the influence of coronary heart disease and hypertension and the result is presented in **Table 2**.

167 After adjustment for coronary heart disease, the IVW method indicates AM (OR: 0.993, 95% CI: 0.895-

168 1.102, P = 0.897), MO (OR: 0.942, 95% CI: 0.857-1.034, P = 0.207), and MA (OR: 0.996, 95% CI: 0.931-1.066,

169 P = 0.902) were not associated with PD risk, and reversely PD was also not correlated with migraine risks.

- 170 This bidirectional null association was supported by the results found by MR-Egger, weighted median, and
- 171 MR-PRESSO methods. Similarly, migraine was not associated with PD risk and vice-versa when controlled
- 172 for the confounding effect of hypertension.

173 3.1.3. Assessment of assumptions

174 Firstly, for the relevance assumption, instrumental variables related to migraine and PD were selected from 175 the recent GWASs with large sample sizes, and SNPs with an F statistic of less than 10 were excluded, thus 176 making it unlikely to induce weak instrument bias. Secondly, for the independence assumption, the 177 selected SNPs were identified to be related to coronary heart disease and hypertension, which were the 178 confounding factors in the association between migraine and PD. To avoid this bias, we performed the MVMR to control the confounding effect, and the association between migraine and PD was still robust. 179 180 Thirdly, for the exclusion restriction assumption, we clumped SNPs at a restricted standard to make the 181 SNPs independent of each other, and modified Q tests were conducted to identify the outlier pleiotropic 182 SNPs. Besides, the MR-Egger regression intercept term indicated there was no significant horizontal 183 pleiotropy among the instruments.

184 **3.2. Genetic association analyses**

Although no obvious causality was found between migraine and PD, we further attempted to investigate whether they were genetically correlated via global/local genetic correlation and tissue expression analyses.

188 3.2.1. Global Genetic Correlation

We used LDSC to investigate the global genetic correlation between PD and migraine based on their corresponding GWAS summary statistics. The LD score regression showed that AM ($r_g = -0.061$, P = 0.127), MA ($r_g = -0.047$, P = 0.516), MO ($r_g = -0.063$, P = 0.492) were generally not related to PD based on GWASs results.

193 3.2.2. Local Genetic Correlation

Although we didn't observe a significant genetic correlation between PD and migraine (including AM, MA, and MO), we then tested whether PD had a genetic correlation with migraine locally. We used ρ -HESS to

investigate the local genetic correlation between PD and migraine. The results of local genetic correlation
analyses between AM and PD are presented in Fig. 2 and Supplementary Table S3. After correcting for
multiple testing (*P*<0.05/1703), no significant local genetic correlation between AM and PD was observed.
As for the migraine subtypes, we discovered MO and PD (Supplementary Fig. 3 and Supplementary
Table S4) or MA and PD (Supplementary Fig. 4 and Supplementary Table S5) were also not locally
correlated in any specific genomic region.

202 3.2.3. Tissue expression analyses

The tissue expression analyses showed GWAS associations related to AM were significantly enriched in colon sigmoid tissue, while GWAS data related to PD were significantly enriched in 6 brain tissues, with the most significant enrichment in Frontal Cortex BA9 (**Fig. 3**). However, genetic data related to MO and MA were not enriched in any GTEx v8 tissue (**Supplementary Fig. S5**). Based on the above results, we discovered that the expression of migraine and PD did not share any same tissue.

208 4. Discussion

Using the latest and largest GWAS summary data related to migraine and PD, we assessed their bidirectional causality via the univariate and multivariate MR analyses but failed to support their causal relationship. We further investigated their genetic association through the global/local genetic correlation and tissue expression analyses, and the results indicated migraine and PD were unlikely to be genetically correlated.

Previous observational studies have tried to investigate the relationship between migraines and PD⁶⁻¹³, but the sample size was relatively limited and the findings were contradictory. The possible mechanism to support the relationship between migraine and PD is mainly reflected in dopaminergic pathways. It was suggested that people who suffered from migraine had chronic dopaminergic hypofunction and dopamine receptor hypersensitivity^{10,40}, and the degeneration of dopamine neurons in dopaminergic

219 pathways is the key hallmark of PD^{15,41}. In this study, we aimed at exploring the causality and genetic 220 relationship between migraine and PD based on GWAS results. Our MR and genetic correlation analyses 221 didn't support a significant causality and genetic relationship between migraine and PD. A possible 222 explanation is that over 200 genes that participate in broad dopaminergic pathways⁴², migraine, and PD 223 may be affected by different genes among these genes to dysregulate dopaminergic pathways. 224 Our study has several strengths that are worth pointing out. First of all, our GWAS data related to migraine 225 and PD both came from the recent large-scale surveys, the sample sizes of which were much larger than 226 previous observational studies. In addition, the associations between PD and migraine subtypes were 227 investigated in this study, which was neglected by previous research. Furthermore, the MR and genetic 228 association analyses could avoid reverse causality and confounding bias from conventional epidemiology 229 studies. 230 Despite the above advantages, the findings from our study should be interpreted within the context of 231 several limitations. For example, the GWAS sample size of PD and migraine needs further extension, e.g., 232 the 23andMe samples are not included in publicly available GWAS summary statistics due to the data 233 release policy of 23andMe^{16,18}. Besides, GWASs could only capture common genetic variations that related 234 to diseases, variations like copy number variations^{43,44} and rare mutations^{45,46} were not included, which 235 are also important components of the genetic architecture of diseases. Lastly, the genetic data we used 236 are largely Europeans, further GWASs of PD and migraine performed in non-European populations are 237 warranted to confirm our results in this study. 238 To sum up, we performed a series of analyses including MR, genetic correlation, and tissue enrichment

analyses to investigate the causal and genetic relationship between migraine and PD based on their GWAS

240 datasets. Our result didn't find clues for the relationship between migraine and PD by current GWAS results,

241 however, this conclusion needs further confirmed in larger sample GWASs and different ethnic groups.

242 **5. Contributors**

- 243 J.L. designed the study and edited the manuscript. M.-G.D. designed the study, performed the statistical
- analysis, and drafted the manuscript. X.Z. drafted and edited the manuscript. F.L., K.W., L.L., M.-J.Z., and
- 245 **Q.F.** reviewed and edited the manuscript.

246 **6. Declaration of Interests**

247 All authors declare no financial or non-financial competing interests.

248 **7. Acknowledgments**

249 We acknowledge the participants from the International Headache Genetics Consortium.

250 8. Data Sharing Statement

- 251 GWAS summary statistics for migraine and subtypes were available at International Headache Genetics
- 252 Consortium (http://www.headachegenetics.org/), and Parkinson's disease associated data could be
- 253 obtained from the International Parkinson's Disease Genomics Consortium (<u>https://www.pdgenetics.org/</u>).

254 9. Funding

255 This study received no funding.

256 **10. Ethics approval**

257 The data sets used were all public available, and the ethical approvals were obtained in the original papers.

258 **11. Consent to participate/publish**

259 Not applicable.

260 **12. Reference**

- 261 1. Headache Classification Committee of the International Headache Society (IHS) The International
- 262 Classification of Headache Disorders, 3rd edition. *Cephalalgia : an international journal of headache*. Jan
- 263 2018;38(1):1-211. doi:10.1177/0333102417738202

- 264 2. Choi KW, Chen CY, Stein MB, et al. Assessment of Bidirectional Relationships Between Physical Activity
- and Depression Among Adults: A 2-Sample Mendelian Randomization Study. JAMA psychiatry. Apr 1
- 266 2019;76(4):399-408. doi:10.1001/jamapsychiatry.2018.4175
- 267 3. Altamura C, Corbelli I, de Tommaso M, et al. Pathophysiological Bases of Comorbidity in Migraine.
- 268 Frontiers in human neuroscience. 2021;15:640574. doi:10.3389/fnhum.2021.640574
- 269 4. Daghlas I, Guo Y, Chasman DI. Effect of genetic liability to migraine on coronary artery disease and
- atrial fibrillation: a Mendelian randomization study. *European journal of neurology*. Mar 2020;27(3):550-
- 271 556. doi:10.1111/ene.14111
- 5. Thomas B, Beal MF. Parkinson's disease. *Human molecular genetics*. Oct 15 2007;16 Spec No. 2:R183-
- 273 94. doi:10.1093/hmg/ddm159
- 274 6. van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? *Clinical*
- 275 Neurology and Neurosurgery. 1992/01/01/ 1992;94:168-170. doi:<u>https://doi.org/10.1016/0303-</u>
- 276 <u>8467(92)90060-G</u>
- 277 7. Lorentz IT. A Survey of Headache in Parkinson's Disease. *Cephalalgia : an international journal of*278 *headache*. 1989;9(2):83-86. doi:10.1046/j.1468-2982.1989.0902083.x
- 8. Sampaio Rocha-Filho PA, Leite Souza-Lima CF. Parkinson's Disease and Headaches: A Cross-Sectional
- 280 Study. Headache. May 2020;60(5):967-973. doi:10.1111/head.13815
- Scher AI, Ross GW, Sigurdsson S, *et al.* Midlife migraine and late-life parkinsonism: AGES-Reykjavik
 study. *Neurology*. Sep 30 2014;83(14):1246-52. doi:10.1212/wnl.00000000000840
- 283 10. Wang HI, Ho YC, Huang YP, Pan SL. Migraine is related to an increased risk of Parkinson's disease: A
- 284 population-based, propensity score-matched, longitudinal follow-up study. *Cephalalgia : an international*
- 285 *journal of headache*. Dec 2016;36(14):1316-1323. doi:10.1177/0333102416630577
- 286 11. Nunes JC, Costa Bergamaschi EN, Freitas FC, et al. Prevalence of headache in patients with Parkinson's
- 287 disease and its association with the side of motor symptom onset. *Neurological sciences : official journal*
- 288 of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. Apr
- 289 2014;35(4):595-600. doi:10.1007/s10072-013-1571-x
- 290 12. Suzuki K, Okuma Y, Uchiyama T, et al. The prevalence, course and clinical correlates of migraine in
- 291 Parkinson's disease: A multicentre case-controlled study. *Cephalalgia : an international journal of headache*.
- Aug 2018;38(9):1535-1544. doi:10.1177/0333102417739302

- 13. Angelopoulou E, Papadopoulos AN, Spantideas N, Bougea A. Migraine, Tension-Type Headache and
- 294 Parkinson's Disease: A Systematic Review and Meta-Analysis. *Medicina (Kaunas, Lithuania)*. Nov 20
- 295 2022;58(11)doi:10.3390/medicina58111684
- 296 14. Gervil M, Ulrich V, Kaprio J, Olesen J, Russell MB. The relative role of genetic and environmental factors
- 297 in migraine without aura. *Neurology*. Sep 22 1999;53(5):995-9. doi:10.1212/wnl.53.5.995
- 15. Kalia LV, Lang AE. Parkinson's disease. *Lancet (London, England)*. Aug 29 2015;386(9996):896-912.
- 299 doi:10.1016/s0140-6736(14)61393-3
- 16. Hautakangas H, Winsvold BS, Ruotsalainen SE, et al. Genome-wide analysis of 102,084 migraine cases
- identifies 123 risk loci and subtype-specific risk alleles. *Nature genetics*. Feb 2022;54(2):152-160.
- 302 doi:10.1038/s41588-021-00990-0
- 303 17. Gormley P, Anttila V, Winsvold BS, *et al.* Meta-analysis of 375,000 individuals identifies 38
 304 susceptibility loci for migraine. *Nature genetics.* Aug 2016;48(8):856-66. doi:10.1038/ng.3598
- 18. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and
- heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *The Lancet Neurology*. Dec 2019;18(12):1091-1102. doi:10.1016/s1474-4422(19)30320-5
- 19. Hess AS, Abd-Elsayed A. Observational Studies: Uses and Limitations. In: Abd-Elsayed A, ed. Pain: A
- 309 *Review Guide*. Springer International Publishing; 2019:123-125.
- 310 20. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. *Cold Spring Harbor*
- 311 *perspectives in medicine*. Jan 4 2022;12(1)doi:10.1101/cshperspect.a040501
- 312 21. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. In: Livingston EH, Lewis RJ, eds. JAMA
- 313 *Guide to Statistics and Methods*. McGraw-Hill Education; 2019.
- 22. Lee KJ, Lee SJ, Bae HJ, Sung J. Exploring the causal inference of migraine on stroke: A Mendelian
- randomization study. *European journal of neurology*. Jan 2022;29(1):335-338. doi:10.1111/ene.15101
- 23. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies.
- 317 International journal of epidemiology. Jun 2011;40(3):755-64. doi:10.1093/ije/dyr036
- 318 24. Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables
- 319 for modifiable risk factors. *Statistical methods in medical research*. Jun 2012;21(3):223-42.
- 320 doi:10.1177/0962280210394459
- 321 25. Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. Oct 1
- 322 2015;526(7571):68-74. doi:10.1038/nature15393

26. Purcell S, Neale B, Todd-Brown K*, et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics.* Sep 2007;81(3):559-75. doi:10.1086/519795

326 27. Bowden J, Spiller W, Del Greco MF, et al. Improving the visualization, interpretation and analysis of

327 two-sample summary data Mendelian randomization via the Radial plot and Radial regression.

328 International journal of epidemiology. Aug 1 2018;47(4):1264-1278. doi:10.1093/ije/dyy101

28. Horton MK, Robinson SC, Shao X, et al. Cross-Trait Mendelian Randomization Study to Investigate

330 Whether Migraine Is a Risk Factor for Multiple Sclerosis. *Neurology*. Mar 28 2023;100(13):e1353-e1362.

331 doi:10.1212/wnl.000000000206791

332 29. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human

333 genotype-phenotype associations. *Bioinformatics (Oxford, England)*. Nov 1 2019;35(22):4851-4853.

doi:10.1093/bioinformatics/btz469

335 30. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian

randomization in the single-sample and two-sample summary data settings. *International journal of epidemiology*. Jun 1 2019;48(3):713-727. doi:10.1093/ije/dyy262

338 31. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases

and traits. Nature genetics. 2015/11/01 2015;47(11):1236-1241. doi:10.1038/ng.3406

340 32. Shi H, Kichaev G, Pasaniuc B. Contrasting the Genetic Architecture of 30 Complex Traits from Summary
341 Association Data. *American journal of human genetics*. Jul 7 2016;99(1):139-53.
342 doi:10.1016/j.ajhg.2016.05.013

343 33. Shi H, Mancuso N, Spendlove S, Pasaniuc B. Local Genetic Correlation Gives Insights into the Shared

Genetic Architecture of Complex Traits. *American journal of human genetics*. Nov 2 2017;101(5):737-751.

345 doi:10.1016/j.ajhg.2017.09.022

34. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data.

347 *PLoS computational biology*. Apr 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219

348 35. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic

349 associations with FUMA. *Nature communications*. Nov 28 2017;8(1):1826. doi:10.1038/s41467-017-01261-

350 5

351 36. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science (New York,*

352 *NY)*. Sep 11 2020;369(6509):1318-1330. doi:10.1126/science.aaz1776

- 353 37. Pardiñas AF, Holmans P, Pocklington AJ, *et al.* Common schizophrenia alleles are enriched in 354 mutation-intolerant genes and in regions under strong background selection. *Nature genetics*. Mar 355 2018;50(3):381-389. doi:10.1038/s41588-018-0059-2
- 356 38. Chen J, Zhang C, Wu Y, Zhang D. Association between Hypertension and the Risk of Parkinson's
- 357 Disease: A Meta-Analysis of Analytical Studies. *Neuroepidemiology*. 2019;52(3-4):181-192.
 358 doi:10.1159/000496977
- 359 39. Chua SKK, Saffari SE, Lee SJY, Tan EK. Association Between Parkinson's Disease and Coronary Artery
- 360 Disease: A Systematic Review and Meta-Analysis. *Journal of Parkinson's disease*. 2022;12(6):1737-1748.
- 361 doi:10.3233/jpd-223291
- 362 40. Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurological sciences :
- 363 official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
- 364 May 2013;34 Suppl 1:S67-70. doi:10.1007/s10072-013-1415-8
- 365 41. Bloem BR, Okun MS, Klein C. Parkinson's disease. *Lancet (London, England)*. Jun 12
 366 2021;397(10291):2284-2303. doi:10.1016/s0140-6736(21)00218-x
- 367 42. Cabana-Domínguez J, Torrico B, Reif A, Fernàndez-Castillo N, Cormand B. Comprehensive exploration
- 368 of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders.
- 369 Translational psychiatry. Jan 10 2022;12(1):11. doi:10.1038/s41398-021-01771-3
- 43. Toft M, Ross OA. Copy number variation in Parkinson's disease. *Genome medicine*. Sep 6 2010;2(9):62.
 doi:10.1186/gm183
- 44. Özaltun MF, Geyik S, Yılmaz Ş G. Screening for Copy Number Variations of the 15q13.3 Hotspot in
- 373 CHRNA7 Gene and Expression in Patients with Migraines. *Current issues in molecular biology*. Sep 7
- 374 2021;43(2):1090-1113. doi:10.3390/cimb43020078
- 45. Hansen RD, Christensen AF, Olesen J. Family studies to find rare high risk variants in migraine. *The*
- 376 *journal of headache and pain*. Dec 2017;18(1):32. doi:10.1186/s10194-017-0729-y
- 46. Gialluisi A, Reccia MG, Modugno N, *et al.* Identification of sixteen novel candidate genes for late onset
- 378 Parkinson's disease. *Molecular neurodegeneration*. Jun 21 2021;16(1):35. doi:10.1186/s13024-021-00455-
- 379 2
- 380

381 Table 1. Univariate Mendelian Randomization to infer the bidirectional relationship between migraine and Parkinson's disease

382	
-----	--

Exposure	Outcome	Nsnp	Methods	OR (95% CI)	n voluo	Casher-ula C	<i>p</i> -value for heterogeneity
			Methods	OR (95% CI)	<i>p</i> -value	Cochran's Q	or pleiotropy [*]
AM	PD	32	IVW	1.016 (0.908, 1.135)	0.785	35.320	0.271
			MR Egger	0.828 (0.602, 1.139)	0.256		0.192
			Weighted median	0.967 (0.828, 1.130)	0.676		
			MR-PRESSO	1.016 (0.908, 1.135)	0.787		
MO	PD	5	IVW	0.944 (0.836, 1.067)	0.358	1.302	0.861
			MR Egger	0.571 (0.189, 1.725)	0.394		0.435
			Weighted median	0.962 (0.828, 1.118)	0.614		
			MR-PRESSO	0.944 (0.881, 1.012)	0.182		
MA	PD	34	IVW	1.006 (0.951, 1.064)	0.846	31.330	0.550
			MR Egger	1.013 (0.887, 1.156)	0.853		0.858
			Weighted median	0.987 (0.910, 1.071)	0.755		
			MR-PRESSO	1.020 (0.959, 1.085)	0.529		
PD	AM	19	IVW	1.003 (0.975, 1.032)	0.817	18.355	0.433
			MR Egger	0.932 (0.851, 1.019)	0.142		0.107
			Weighted median	0.990 (0.950, 1.031)	0.625		
			MR-PRESSO	1.003 (0.975, 1.032)	0.819		
PD	MO	19	IVW	0.956 (0.893, 1.025)	0.207	14.552	0.692
			MR Egger	0.829 (0.692, 0.994)	0.043		0.113
			Weighted median	0.932 (0.845, 1.029)	0.163		
			MR-PRESSO	0.956 (0.899, 1.018)	0.177		
PD	MA	18	IVW	1.032 (0.955, 1.115)	0.430	6.761	0.986
			MR Egger	0.921 (0.764, 1.109)	0.398		0.206
			Weighted median	1.038 (0.932, 1.156)	0.494		
			MR-PRESSO	1.032 (0.982, 1.083)	0.228		

383

[†] *p*-value for heterogeneity based on Cochran's Q statistic.

* *p*-value or pleiotropy based on MR-Egger regression intercept. 384

Abbreviations: AM: any migraine; CI: confidence interval; MA: migraine with aura; MO: migraine without aura; IVW: 385

386 inverse variance weighted; OR: odds ratio; PRESSO: Pleiotropy RESidual Sum and Outlier; SNP: Single-nucleotide

387 polymorphism.

Evenesure	Outerma	Model _	IVW		MR-Egger		Weight median		MR-PRESSO	
Exposure	Outcome		OR (95% CI)	<i>p</i> -value						
AM	PD	а	0.993(0.895, 1.102)	0.897	0.992(0.894, 1.101)	0.879	0.973(0.836, 1.132)	0.723	0.993(0.895, 1.102)	0.897
		b	1.024(0.906, 1.158)	0.702	0.856(0.602, 1.218)	0.388	0.939(0.796, 1.108)	0.459	1.024(0.906, 1.159)	0.705
МО	PD	а	0.942(0.857, 1.034)	0.207	0.944(0.859, 1.037)	0.225	0.940(0.831, 1.063)	0.325	0.942(0.859, 1.033)	0.204
		b	0.934(0.826, 1.057)	0.278	0.928(0.819, 1.051)	0.240	0.909(0.766, 1.080)	0.279	0.934(0.884, 0.988)	0.076
MA	PD	а	0.996(0.931, 1.066)	0.902	0.995(0.930, 1.065)	0.888	1.018(0.926, 1.121)	0.711	0.996(0.930, 1.066)	0.902
		b	1.048(0.978, 1.124)	0.181	1.069(0.999, 1.146)	0.053	1.022(0.920, 1.135)	0.679	1.049(0.978, 1.124)	0.187
PD	AM	а	0.964(0.915, 1.015)	0.168	1.001(0.942, 1.065)	0.962	0.984(0.944, 1.026)	0.444	0.964(0.915, 1.016)	0.170
		b	0.994(0.957, 1.033)	0.761	0.987(0.952, 1.023)	0.477	1.009(0.967, 1.054)	0.677	0.994(0.957, 1.033)	0.764
PD	MO	а	0.948(0.861, 1.045)	0.287	0.959(0.868, 1.061)	0.420	0.929(0.840, 1.026)	0.148	0.949(0.861, 1.045)	0.288
		b	0.991(0.925, 1.062)	0.794	0.990(0.921, 1.064)	0.790	0.967(0.869, 1.075)	0.524	0.991(0.926, 1.060)	0.791
PD	MA	а	1.021(0.926, 1.127)	0.669	1.004(0.908, 1.111)	0.939	1.040(0.931, 1.162)	0.491	1.022(0.926, 1.127)	0.670
		b	1.043(0.964, 1.129)	0.294	0.999(0.984, 1.014)	0.883	1.052(0.938, 1.181)	0.384	1.043(0.964, 1.129)	0.307

388 Table 2 Multivariate Mendelian Randomization to investigate the bidirectional causal relationship between migraine and Parkinson's disease.

^a adjusted for coronary heart disease; ^b adjusted for hypertension.

390 Abbreviations: AM: any migraine; CI: confidence interval; MA: migraine with aura; MO: migraine without aura; IVW: inverse variance weighted; OR: odds ratio;

391 PRESSO: Pleiotropy RESidual Sum and Outlier.

Figure legends

Fig 1. MR leave-one-out analyses of migraine on Parkinson's disease (above) and Parkinson's disease on migraine (below).

Fig 2. Local genetic correlation and genetic covariance between any migraine and Parkinson's disease, and also local SNP heritability estimation for migraine and Parkinson's disease respectively.

Fig 3. Tissue-type enrichments of AM and PD GWAS associations. The red dashed line is the Bonferroni corrected significant level. Tissues that showed significant enrichment (corrected P < 0.05) are shown in yellow. AM = Any migraine; PD = Parkinson's disease.





